For early-stage head and neck cancer (HNC), surgery (S) or radiotherapy (RT) is a standard
treatment. The multidisciplinary approach, which includes multimodality treatment with S …

Background Three‐weekly high‐dose cisplatin (100 mg/m2) is considered the standard
systemic regimen given concurrently with postoperative or definitive radiotherapy in locally …

Background The impact of low-level laser therapy (LLLT) to prevent oral mucositis in
patients treated with exclusive chemoradiation therapy remains unknown. This study …

BACKGROUND Circulating cell-free DNA methylation testing in blood has recently received
regulatory approval for screening of colorectal cancer. Its application in other clinical …

Nanoparticle (NP) chemotherapeutics can improve the therapeutic index of
chemoradiotherapy (CRT). However, the effect of NP physical properties, such particle size …

Background Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …

Objectives To characterize the recognized but poorly understood long-term toxicities of
radiation therapy (RT) for head and neck cancer (HNC). Materials and methods We …

Human papillomavirus positive oropharyngeal cancer (HPV-positive OPC) is a distinct
subtype of head and neck carcinoma (HNC) distinguished from HPV-negative HNC by its …

Recent advances have permitted successful therapeutic targeting of the immune system in
head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets …

Introduction Concurrent chemoradiation is the standard of care in inoperable locally
advanced squamous cell head and neck cancers. The most widely accepted schedule of …